TICKERNERD
Menu
MEDPMEDPHealthcare · Diagnostics & Research

MEDP Stock Forecast: Medpace Holdings, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$586
−0.78% on the day

The 13 Wall Street analysts covering Medpace Holdings, Inc. hold a median 12-month price target of $605 — +3.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$16.5B
Ticker Nerd rank
97 / 100
Median analyst target
$605
Analysts covering
13
Revenue$707.3M+17.2% y/y
Operating income$146.8M
Net income$121.4M
Free cash flow$138.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.5%
1M
−0.7%
YTD
+4.4%
1Y
+20.7%
From 52W high
−5.5%
From 52W low
+49.0%
$393
$621
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MEDP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medpace Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Revisions
95
Issuance
87
Volatility
80
Growth
74
Accruals
72
Momentum
71
Value
68
Size
11

Quality (98): The business earns solid, repeatable profits on what it owns.

Value (68): The shares cost a lot relative to the profits and assets behind them.

Size (11): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MEDP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MEDP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700Oct 25Jan 26Apr 26Jul 26MEDPHigh $692Median $605Low $370

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
2 Buy10 Hold1 Sell
Low $370Median $605High $692

The green dot is the last close — the median target sits +3.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 July 2026BairdMaintainsNeutral$547 → $624
24 July 2026BMO CapitalMaintainsMarket Perform$400 → $600
24 July 2026MizuhoMaintainsOutperform$586 → $665
24 July 2026RBC CapitalMaintainsOutperform$484 → $692
24 July 2026TD CowenMaintainsHold$419 → $492
24 July 2026Truist SecuritiesMaintainsHold$462 → $609
13 July 2026MizuhoMaintainsOutperform—
13 July 2026MizuhoMaintainsOutperform$495 → $586
8 July 2026BairdDowngradeNeutral$477 → $547
8 July 2026BairdDowngradeNeutral—
7 July 2026JefferiesDowngradeHold$490 → $515
7 July 2026JefferiesDowngradeHold—
24 Apr 2026BairdMaintainsOutperform—
24 Apr 2026BarclaysMaintainsEqual-Weight—
24 Apr 2026BMO CapitalMaintainsMarket Perform—
24 Apr 2026RBC CapitalMaintainsOutperform—
6 Mar 2026BarclaysUpgradeEqual-Weight—
3 Mar 2026RBC CapitalInitiatesOutperform—
18 Feb 2026TD CowenUpgradeHold—
13 Feb 2026JefferiesUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MEDP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MEDP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Medpace Holdings, Inc. returned +20.7% against +18.5% for the S&P 500, dividends included.

MEDP vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Oct 25Jan 26Apr 26Jul 26MEDPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MEDP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.5%
Analysts raising
9
Analysts cutting
0
Fundamentals

Medpace Holdings, Inc. (MEDP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
34.7×

Cheaper than 22% of US stocks

Price / sales
5.9×

Cheaper than 22% of US stocks

Price / book
38.0×

Cheaper than 3% of US stocks

EV / EBITDA
26.4×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
17.2%

Higher than 66% of US stocks

Earnings growth (YoY)
34.5%

Higher than 68% of US stocks

Gross margin
28.5%

Higher than 32% of US stocks

Operating margin
20.8%

Higher than 80% of US stocks

Net margin
17.7%

Higher than 80% of US stocks

Returns & dividend
Return on equity
162.2%

Higher than 98% of US stocks

Return on assets
20.1%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Medpace Holdings, Inc. (MEDP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Medpace Holdings, Inc. has a market value of $16.5B and an enterprise value of $16.1B.

  • Revenue in the twelve months to 30 June 2026: $2.8B. The latest quarter grew 17.2% year on year.

  • Net income over the same four quarters: $491.5M, a 17.7% net margin.

  • Diluted earnings per share, trailing twelve months: $17.06.

  • Free cash flow in the twelve months to 30 June 2026: $706.7M.

  • Medpace Holdings, Inc. spent $299.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 27.9M.

  • Trailing P/E: 34.7×; forward P/E: 30.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Medpace Holdings, Inc. employs 6,500 people — $428K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Sept 2026

Data provided by Twelve Data

Peers

MEDP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
MEDPMedpace Holdings, Inc.$16.5B
97
RVTYRevvity, Inc.$14.2B
93
CRLCharles River Laboratories International, Inc.$13.8B
88
GHGuardant Health, Inc.$20.8B
48
ICLRIcon PLC$12.1B
69
DGXQuest Diagnostics, Inc.$26.2B
94
LHLabcorp Holdings, Inc.$26.9B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Medpace Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MEDP news & analysis

Why Medpace (MEDP) is a Top Growth Stock for the Long-Term

Zacks Investment Research · 1 Sept 2026positive

Zacks Investment Research highlighted Medpace (MEDP) as a top growth stock for the long term, citing the Zacks Style Scores system as a way for investors to identify top-rated stocks based on their investing style. The piece positions MEDP favorably within this screening framework.

Why it matters — MEDP watchers would care because the article highlights the company as a top-rated long-term growth stock according to Zacks' screening metrics, which could raise its visibility among investors.

Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike

Investors Business Daily · 26 Aug 2026positive

Medpace stock is trading back below a buy point of 628.92 after a July spike. The medical research contractor reported an earnings beat for its second quarter.

Why it matters — A MEDP watcher would care that the company's recent second-quarter earnings beat coincides with the stock returning to a potential entry level near its buy point.

CON vs. MEDP: Which Stock Should Value Investors Buy Now?

Zacks Investment Research · 26 Aug 2026neutral

Zacks Investment Research published an analysis comparing Concentra Group and Medpace as potential value-investing opportunities in the Medical Services sector. The piece asks which of the two stocks currently presents the better value opportunity.

Why it matters — MEDP watchers would care because the article places Medpace in a comparative value assessment against a peer within its sector, potentially influencing how investors evaluate the stock.

What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock

The Motley Fool · 26 Aug 2026neutral

Medpace Holdings CEO August Troendle sold 15,978 shares at a weighted-average price of $623.93 over two trading days ending Aug. 24, 2026, totaling roughly $10 million. The sale represented 3% of his direct equity holdings and 0.3% of his total combined stake.

Why it matters — Investors tracking insider activity would note the CEO's share sale as a signal of reduced direct ownership in the company, though the relatively small portion of his total stake suggests limited impact.

Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?

Zacks Investment Research · 21 Aug 2026neutral

Medpace reported earnings 30 days ago, and the stock has risen 1.1% since that report. The article examines what may be next for the company following the earnings release.

Why it matters — MEDP watchers would care because the post-earnings stock movement and outlook are relevant to assessing the company's recent performance and near-term trajectory.

FAQ

Frequently asked questions about MEDP stock

What is the MEDP stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Medpace Holdings, Inc. have a median 12-month price target of $605, with estimates ranging from $370 to $692. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MEDP stock a buy right now?

Of the 13 analysts covering Medpace Holdings, Inc., 2 rate it a Buy, 10 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Medpace Holdings, Inc. 97 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MEDP?

As at 8 Sept 2026, Medpace Holdings, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will MEDP stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +3.1% from the last close, and Ticker Nerd's factor model ranks Medpace Holdings, Inc. 97 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MEDP stock forecast for 2030?

No analyst covering Medpace Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $370 to $692 over the next 12 months.

How has MEDP stock performed over the past year?

Medpace Holdings, Inc. returned +20.7% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Medpace Holdings, Inc. do?

Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies.

What is the latest news on MEDP?

The most recent item we track (Zacks Investment Research, 1 Sept 2026): "Why Medpace (MEDP) is a Top Growth Stock for the Long-Term". Zacks Investment Research highlighted Medpace (MEDP) as a top growth stock for the long term, citing the Zacks Style Scores system as a way for investors to identify top-rated stocks based on their investing style. The piece positions MEDP favorably within this screening framework.

Company

About Medpace Holdings, Inc.

Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support. The company also offers specialized laboratory and trial support capabilities such as central laboratory services, bioanalytical testing, imaging core laboratory services, and cardiac safety assessments. Medpace serves clients across North America, Europe, Asia, South America, Africa, and Australia, playing a central role in helping sponsors run complex clinical programs and advance medical products through development.

CEO Dr. August James Troendle M.D. · 6,500 employees · United States · https://www.medpace.com